This episode From the Vault looks back at the first episode dedicated entirely to nutrition and NASH with distinguished guest, Prof. Shira Zelber-Sagi. In this conversation, she joins Ken Cusi, Jörn Schattenberg, Louise Campbell and Roger Green to explore the psychology of decision-making around diet and professional support.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This final conversation continues on the subject of evaluating the GLP-1 drug class and its potential impact on lean muscle loss. The final question of Season 4, Episode 34 considers the big picture scope of what has been learned in the last month that might affect research or conceptual thinking going forward.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation considers results from the Phase 2b study for the dual GLP-1/glucagon agonist pemvidutide, which wanders into the importance of the actual GLP-1-to-glucagon impact ratio, potentially significant safety signals that remain to be fully studied, and the subject of how much lean muscle mass these agents produce.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. This conversation focuses on the increasing importance of omics and potentially powerful weight-loss therapies presented at the ADA meeting. Other major themes in this session include insights on the role of artificial intelligence and epigenetics.
Stephen Harrison, Mazen Noureddin, Jörn Schattenberg, Louise Campbell and Roger Green unpack compelling drug development stories from this month’s EASL Congress and ADA meetings. The session explores a range of topics around the subject of drug development, including notes on orals versus injectables, diabetes medications with potential in the NASH space, new clinical trial data, different drug classes and much more.
Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the presentations of interest from EASL Congress 2023. In this conversation, Ian points to a presentation on automated FIB-4 score calculation and e-reminders to detect advanced liver disease in patients with type 2 diabetes. The group goes on to explore big picture questions on the topic of disease identification and tease the differences between hepatology and private practices and management of a population-level disease.
Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss the new NAFLD/NASH nomenclature shared at EASL Congress 2023. The groups outlines what the changes entail and shares practical considerations around how to implement the changes in different settings and with patients.
Sven Francque and Ian Rowe join Jörn Schattenberg and Roger Green to discuss critical and/or compelling presentations and insights from the recently concluded EASL Congress in Vienna. The session focuses on new nomenclature and emerging stories around patient identification, NITs, fibrosis resolution and more.
Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. This final conversation considers important topics yet to be addressed in the preceding sessions. One of the prevailing themes explored is the potential of NASH drugs as adjuvant therapy.
Stephen Harrison and Jörn Schattenberg join Roger Green to digest and discuss key takeaways from the recently concluded EASL Congress 2023 and ADA 83rd Scientific Sessions. In this conversation, the group moves on from analysis around resmetirom to discuss other drug classes in the therapeutic landscape.
